Develops gene therapies for neurological diseases.
Mar 2026Revenue $34.6M/yrExpenses $158M/yr
No trendCash runway ≈ 4 months from Mar 2026
Figures by year
When will Sangamo Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Mar 2026, revenue was $34.6M and expenses $158M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $39.6M | $161M | −$121M |
| Dec 2024 | $57.8M | $162M | −$104M |
| Dec 2023 | $176M | $450M | −$274M |
| Dec 2022 | $111M | $313M | −$201M |
| Dec 2021 | $111M | $294M | −$183M |
| Dec 2020 | $118M | $248M | −$130M |
| Dec 2019 | $102M | $208M | −$105M |
| Dec 2018 | $84.5M | $162M | −$77.2M |
| Dec 2017 | $36.6M | $92.9M | −$56.4M |
| Dec 2016 | $19.4M | $91.9M | −$72.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.